Background and Purpose-In hemodialysis patients, previous reports have described a high prevalence of cerebral microbleeds (CMBs), but no longitudinal studies have been performed to determine the clinical significance of CMBs in these patients. In this study, we investigated whether the presence of CMBs was a predictor of future strokes in hemodialysis patients. Methods-Cranial MRI, including T2*-weighted magnetic resonance imaging, was performed on 179 hemodialysis patients with no past history of cerebrovascular events. The patients were followed prospectively until death or renal transplantation. We used the Cox proportional hazards model with inverse probability of treatment weighting using the propensity score to compare the event-free survivals of patients with/without CMBs. For sensitivity analyses, stratification by propensity score quintile and regression adjustment were used. Results-CMBs were detected in 45 of the 179 patients. During a median follow-up period of 5.0 years, stroke occurred in 24 patients, including 12 with intracerebral hemorrhage and 12 with cerebral infarctions. Cox proportional hazards analysis with inverse probability of treatment weighting using the propensity score revealed that the presence of CMBs was a strong and significant predictor of intracerebral hemorrhage (hazard ratio, 26.53; 95% confidence interval, 2.88-244.90) but not cerebral infarction (hazard ratio, 0.91; 95% confidence interval, 0.25-3.34). Sensitivity analyses yielded similar results. Conclusions-This study showed that the presence of CMBs was an independent and strong predictor of intracerebral hemorrhage in stroke-free hemodialysis patients, indicating that hemodialysis patients with CMBs should be carefully monitored for future onset of intracerebral hemorrhage.
T he recent development of gradient-echo T2*-weighted magnetic resonance imaging (MRI) 1 has enabled the highly accurate detection of previous cerebral microbleeds (CMBs) that are hardly detectable by conventional computed tomographic scanning and MRI. CMBs are seen as small, round hypointense lesions on T2*-weighted MRI, pathologically representing focal hemosiderin deposition associated with previous microhemorrhages resulting from bleeding-prone small-vessel diseases, such as hypertensive arteriopathy (including lipohyalinosis and arteriolosclerosis) and cerebral amyloid angiopathy. [1] [2] [3] [4] Among the risk factors for CMBs, older age, [5] [6] [7] [8] [9] hypertension, [4] [5] [6] 8, 9 diabetes mellitus (DM), 7 low total cholesterol, 8, 10 and APOE 4 carriership 11 have been demonstrated in cohorts with strokes or community-dwelling elderly individuals. In particular, older age and hypertension are most commonly associated with CMBs. It has also been reported that CMBs predict the future risk of spontaneous intracerebral hemorrhage (ICH) and ischemic stroke (IS) in patients after ICH, 12, 13 IS, [12] [13] [14] and transient ischemic attack, [12] [13] [14] as well as in strokefree individuals. 15, 16 Although CMBs are being increasingly detected by the more frequent use of sensitive MRI techniques, the differences in the sensitivity of the MRI techniques used should be taken into consideration. Previous studies have reported that the prevalence of CMBs was 3.1% to 23.5% in healthy populations without cerebrovascular disease, 5, 6, 9 18% to 68% in patients with IS, 6, 9 and 47% to 80% in patients with ICH. 6, 9 In hemodialysis patients, who have a much higher incidence of strokes (particularly ICH) than the general population, [17] [18] [19] previous reports including ours have described a high prevalence of CMBs of 19.3% to 35%. [20] [21] [22] However, there have been no longitudinal studies to determine the clinical significance of CMBs in hemodialysis patients. In this study, which followed up on our previous cross-sectional study, we investigated whether the presence of CMBs was a predictor of future stroke (particularly ICH) in hemodialysis patients.
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Methods

Study Participants
The study population was derived from our previous cross-sectional study. 20 In short, the subjects were selected from the total population of hemodialysis patients (n=214) that had been treated at Osaka City University Hospital and Ohno Memorial Hospital from April 2006 to October 2009. Of the 214 hemodialysis patients, 21 were excluded because of a previous history or symptoms of stroke, autosomal dominant polycystic kidney disease, chronic infection, chronic inflammatory disease, or malignant disease. Six patients declined to participate, and the remaining 187 were studied. The MR images were assessed independently by 2 neuroradiologists who were blinded to any clinical information. Of the 187 patients who underwent MRI, 8 cases with diagnostic inconsistencies were excluded, resulting in 179 cases that were examined for this study. This study protocol was approved by the ethics committee of Osaka City University Graduate School of Medicine (number 1415). Informed consent was obtained from all subjects before their participation in the study.
Magnetic Resonance Imaging
All participating patients had a brain MRI that used a superconducting magnet at a field strength of 1.5 T on proton density, T1-, T2-weighted fluid-attenuated inversion recovery MRI, and 2-dimensional gradient-echo (repetition time, 606 ms; echo time, 23 ms; flip angle, 18°-20°; field of view, 200 mm; acquisition matrix, 256×175-224) T2*-weighted MRI in axial planes at 5-mm thick slices with an interslice gap of 1.5 mm.
CMBs were defined as focal areas of signal loss consisting of homogeneous, rounded lesions with diameters of 2 to 5 mm on T2*-weighted MRI. Hypointensities of the globus pallidus, which probably represented calcification or flow void artifacts of the pial vessel, were excluded.
Lacunar infarcts were defined as focal areas ≥3 mm and <15 mm in diameter on both T1-and T2-weighted MRI, which were visible as low-signal intensity areas on T1-weighted MRI and as high-signal intensity areas on T2-weighted MRI.
White matter hyperintensities, such as periventricular hyperintensity (PVH) and deep and subcortical white matter hyperintensity (DSWMH), were defined as focal areas of increased signal intensity on T2-weighted and fluid-attenuated inversion recovery MRI, if there was no corresponding signal alteration on the T1-weighted MRI.
The MR images were assessed independently by 2 neuroradiologists who were blinded to any clinical information. As cases with inconsistencies were excluded from the study, of the 187 patients who underwent MRI, 8 cases with diagnostic inconsistencies were excluded, resulting in 179 cases that were examined for this study.
Definition of Traditional Risk Factors
Hypertension was defined by (1) the administration of antihypertensive agents or a history of this disorder; (2) a systolic blood pressure >140 mm Hg; or (3) a diastolic blood pressure >90 mm Hg, and 23 Dyslipidemia was defined if the subject exhibited low-density lipoprotein cholesterol >140 mg/ dL, triglyceride >150 mg/dL, and high-density lipoprotein cholesterol <40 mg/dL or had undergone medical treatment for hyperlipidemia. Blood samples were taken from the arterial line before the hemodialysis sessions.
Ischemic heart disease was defined as either angina or a history of myocardial infarction, coronary artery bypass surgery, or percutaneous coronary intervention. Angina was diagnosed by exercise electrocardiography, myocardial perfusion imaging, or coronary angiography. Atrial fibrillation was diagnosed based on electrocardiographic findings or a previous history of atrial fibrillation. 
Outcome Data Collection
The patients were followed up prospectively until March 2014 or death or renal transplantation, with a median follow-up period of 5.0 (1.0-6.1) years. We collected the patients' clinical outcome data by directly reviewing all medical records. For 26 patients who moved out of the area of our dialysis hospitals during the follow-up period, outcome data were obtained through questionnaire forms completed by their present attending physicians. No patients were lost to followup. During the follow-up period, 34 patients underwent renal transplantation, and they were censored at the time of transplantation. At the end of follow-up, 90 patients were confirmed to be alive on hemodialysis and 55 were dead. The dates of their stroke events were documented. All stroke events were diagnosed carefully by the attending physician, who was not associated with the study.
Statistical Analysis
Data are summarized as a percentage or the mean±SD or median (25th-75th), whenever appropriate. Differences between groups were examined by the unpaired Student t test or Mann-Whitney U test. Categorical variables were compared using the χ 2 test. The risks of stroke (ICH and cerebral infarction) were compared between patients with or without CMBs using the Kaplan-Meier analysis and Log-rank test. Because the frequency of stroke was not large enough to adjust for the baseline clinical characteristics, 24 a propensity score (PS) 25 of the presence of CMBs was estimated as a data reduction technique using multivariable logistic regression, based on confounding covariates, including age, sex, the presence or absence of lacunar infarcts, PVH, DSWMH, hypertension, DM, dyslipidemia, ischemic heart disease, atrial fibrillation, current smoking, dialysis duration, hemoglobin, systolic blood pressure, diastolic blood pressure, total cholesterol, use of statin, serum albumin, C-reactive protein, body mass index, use of antiplatelet agents, use of warfarin, and use of multiple antithrombotic agents. We used natural log-transformed dialysis duration and C-reactive protein in this regression. The C index of this model was 0.873.
We used the Cox proportional hazards model with inverse probability of treatment weighting using the PS 26, 27 to compare the event-free survival of patients with/without CMBs. For sensitivity analyses, we used 2 additional models: (1) stratification by PS quintile 28 and (2) regression adjustment for the logit of PS. 28 However, PS matching was not possible because we could not create a wellbalanced model of the 2 groups after PS matching. Sex, the presence or absence of CMBs, lacunar infarcts, PVH, DSWMH, hypertension, DM, dyslipidemia, ischemic heart disease, atrial fibrillation, current smoking, and the use of statin, antiplatelet agents, warfarin, and multiple antithrombotic agents were represented by dummy variables (1=men; 0=women; 1=presence, 0=absence; smoker=1, nonsmoker=0; yes=1, no=0) in the logistic analysis. P values of <0.05 were considered statistically significant. These results were obtained using STATA/SE 13.1 for Windows (STATA Corp. LP) and R version 3.1.2 for Windows. Twenty-eight patients (62.2%) had multiple CMBs with counts ranging from 2 to 22. Among the 45 patients with CMBs, 26 (57.8%) were located in the deep brain region, 6 (13.3%) in the lobar region, and 13 (28.9%) in both regions. The patients with CMBs were significantly older than those without CMBs. Systolic blood pressure and the prevalences of hypertension, DM, atrial fibrillation, lacunar infarcts, PVH, and DSWMH in the patients with CMBs were significantly higher than those of the patients without CMBs. There was no significant difference in the other factors between the patients with/without CMBs.
Results
Baseline Characteristics of the Study Subjects
Outcomes
During a median follow-up period of 5.0 (1.2-6.1) years, stroke occurred in 24 patients (13.4%), including 12 patients with ICH and 12 with cerebral infarctions (7 lacunar, 3 atherothrombotic, and 2 cardioembolic infarctions; Table 2 ). The patients with CMBs had significantly higher incidences of stroke and ICH than those without CMBs. 
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The relationship between the distribution of CMBs at baseline and the location of ICH is shown in Table 3 . Of the 12 patients with ICH, 10 patients had CMBs in the deep brain region and 2 patients in the lobar region.
Influence of CMBs on ICH and Cerebral Infarction
Event-free rate curves were generated using the Kaplan-Meier method together with the Log-rank test ( Figure [A] and [B] ). ICH was significantly more common among the patients with CMBs than those without.
The Cox proportional hazards analysis with inverse probability of treatment weighting using the PS revealed that the presence of CMBs was a strong and significant predictor of ICH (hazard ratio, 26.53; 95% confidence interval [CI], 2.88-244.90) but not of cerebral infarction (hazard ratio, 0.91; 95% CI, 0.25-3.34; Table 4 ). Sensitivity analyses yielded similar results (Table 4) .
Discussion
In this study, we investigated the influence of cerebral MRIdiagnosed CMBs as a predictor of future stroke (particularly ICH) in the same cohort as our previous study. 20 As a result, we revealed that the patients with CMBs had a significantly higher incidence of ICH than those without CMBs based on the Kaplan-Meier analysis ( Figure [A] and [B] ). Based on the Cox proportional hazards analysis, after applying PS 25 to adjust for group differences, the presence of CMBs increased the risk of ICH, independent of other cardiovascular risk factors and the presence of small-vessel diseases (lacunar infarcts, PVH, and DSWMH; Table 4 ). In addition, this study revealed that the presence of CMBs was a strong and significant predictor of ICH (hazard ratio, 26.53; 95% CI, 2.88-244.90) but not of cerebral infarction (hazard ratio, 0.91; 95% CI, 0.25-3.34; Table 4 ). This is the first report to reveal that the presence of CMBs is a strong predictor of future ICH in stroke-free hemodialysis patients.
Dialysis patients have a much higher incidence of stroke than the normal population, and strokes in dialysis patients are characterized by a higher incidence of hypertensive ICH compared with those in the general population. 17, 18 Our findings that hemodialysis patients had a high prevalence of CMBs 20 and that the presence of CMB was a predictor of ICH corroborated these epidemiological observations.
Moreover, it has been reported that the presence of CMBs is a strong predictor not only of ICH but also of IS in nondialysis cohorts. [12] [13] [14] [15] [16] To date, only 2 prospective studies 15, 16 have analyzed the relationship between CMBs and subsequent strokes in stroke-free individuals as in our cohort, and both studies showed that CMBs strongly predicted the occurrence of future cerebral infarctions. In contrast, in our present study, the presence of CMBs was a significant and independent predictor of ICH but not of cerebral infarction. Because adjustment for baseline variables was not performed sufficiently for all the variables in the multivariate analysis of the previous studies, 15, 16 those previous results cannot be simply compared with the results of our present study in which the baseline variables were adjusted using PS. 25 Even so, our results clearly indicated that the risk of hemorrhagic stroke was higher in hemodialysis patients with CMBs and also corroborated the aforementioned Figure.
Kaplan-Meier curves of the event-free survival rate (A, intracerebral hemorrhage; B, cerebral infarction) stratified by the presence or absence of cerebral microbleeds (CMBs).
by guest on April 29, 2017 http://stroke.ahajournals.org/ Downloaded from epidemiological characteristics of the dialysis patients. 17, 18 This may be explained by the following mechanisms: (1) hemodialysis patients share the same risk factor profile with patients with ICH, 29 such as a high prevalence of hypertension, low cholesterol, and inflammation, which is thought to increase the incidence of hemorrhagic stroke in hemodialysis patients with CMBs; (2) it is well established that the use of antithrombotic drugs (antiplatelet/anticoagulant drugs) is related to the increased incidence and recurrence of ICH. 30 However, in almost all hemodialysis patients, anticoagulation therapy (systemic heparinization) is necessary during the repeated hemodialysis sessions, and there are many other situations in which antithrombotic therapy can be used, such as in the treatment of coronary heart disease, arteriosclerosis obliterans, peripheral arterial disease, ischemic cerebrovascular disease, and vascular access trouble. The use of these antithrombotic drugs may also increase the occurrence of hemorrhagic stroke in hemodialysis patients with CMBs. Nonetheless, because of the relatively small sample size (n=179) and few outcome events (only 24 strokes), the statistical power of our analysis was limited (with corresponding wide CIs), so that a cohort study using a larger sample size must be conducted in future.
The causes of CMBs are presumed to differ according to the CMB location, 12, 13 as strictly lobar CMBs are mainly caused by cerebral amyloid angiopathy and deep CMBs are mainly caused by hypertensive microangiopathy. Furthermore, it is well established that in Asian populations, in contrast to Western populations, the predominant microangiopathy is hypertension-related rather than cerebral amyloid angiopathy. 12, 13 The risks of ICH and IS in the presence of CMBs are also thought to vary across ethnic groups. 12, 13 In our study, many of the CMBs were located in the deep brain region and many of the ICH were also located in the deep brain region (Table 3) , which further corroborated the aforementioned epidemiological characteristics in dialysis patients. 17, 18 In future studies, the location of CMBs and ethnicities should also be considered.
This study has several limitations. First, in patients with ischemic or hemorrhagic stroke, the risk of ICH increases with the number of CMBs, especially in patients with many (≥5) CMBs. 31 Further studies should elucidate the association between the number of CMBs and the incidence of future strokes in dialysis cohorts. Second, it remains controversial as to whether the presence of CMBs is a useful tool for stratifying the risk of ICH before deciding on antithrombotic or thrombolytic treatments 32 because good quality prospective data in large cohorts are not yet available, particularly about thrombolysis. Further studies must investigate ICH risks in hemodialysis patients with CMBs undergoing antithrombotic or thrombolytic treatments. Third, although we reported the prevalence of CMBs based on conventional 2-dimensional (2D) T2*-weighted MRI, newer techniques, such as 3D T2*-weighted MRI, higher magnetic field strength (3.0 or 7.0 T) MRI, or susceptibility-weighted imaging, might provide different results. 33 Further examinations should be performed using more advanced MRI techniques. Fourth, recently, it has become well established that chronic kidney disease is an independent risk factor of stroke, 29 and CMBs have been reported to be frequently observed in nondialysis chronic kidney disease patients. 34, 35 Therefore, whether the presence of CMBs is a predictor of future stroke, including ICH, should also be studied in nondialysis chronic kidney disease patients.
In conclusion, this study indicated that the presence of CMBs was an independent and strong predictor of ICH in stroke-free hemodialysis patients. To prevent ICH in hemodialysis patients, it is important to monitor these hemodialysis patients with CMBs and provide care accordingly.
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